参松养心胶囊治疗冠心病心功能不全气虚血瘀型的临床疗效及安全性分析

The clinical efficacy and safety of Shensongyangxin capsules in treating coronary heart disease heart failure with qi deficiency and blood stasis syndrome

目的探讨参松养心胶囊治疗冠心病心功能不全气虚血瘀型的临床疗效及安全性。方法 80例冠心病心功能不全气虚型的患者随机分为对照组与观察组各40例。对照组予西医常规治疗,观察组在此基础上给予参松养心胶囊。比较两组患者的疗效、治疗前后6min步行试验、治疗前后心电图及ESV、EDV与LVEF及安全性。结果对照组的总有效率为72.50%(29/40),显著低于观察组92.50%(37/40)(P<0.05);观察组治疗后6min步行试验与对照组比较,P<0.05;两组治疗后ESV、EDV及LVEF相比,P<0.05。结论参松养心胶囊治疗冠心病心功能不全气虚血瘀型的临床疗效显著。

Objective To explore the clinical efficacy and safety of Shensongyangxin capsules in treating coronary heart disease heart failure with qi deficiency and blood stasis syndrome. Methods Eighty coronary heart disease patients with heart failure and qi deficiency syndrome were chosen and randomly divided into two groups of 40 patients： the control group and the observation group. Patients in the control group were treated by routine western medicine, while patients in the observation group were treated by Shensongyangxin capsules in addition to routine western medicine. The clinical efficacy, the 6-minute walking test results, the electrocardiogram, ESV, EDV and LVEF before and after the treatment, and the safety of the two groups were compared. Results The total effective rate of control group was 72.50%（29/40）, which was significantly lower than that of the observation group 92.50%（37/40） （P 〈 0.05）; The observation group and the control group were significantly different in the 6-minute walking test （P 〈 0.05）; The two groups were significantly different in the post-treatment ESV, EDV and LVEF （P 〈 0.05）. Conclusion Shensongyangxin capsules had significant clinical effect in treating coronary heart disease heart failure with qi deficiency and blood stasis syndrome.